Smartphone ECG for Heart Attack

(STLEUISII Trial)

This trial aims to test a new device called the AliveCor 12-lead ECG. The device helps diagnose heart attacks, such as STEMI and NSTEMI, as effectively as current standard equipment. The trial focuses on comparing its accuracy to existing 12-lead ECG machines in emergency settings. Individuals experiencing chest pain and visiting the emergency department may qualify for this trial. As an unphased trial, it offers participants the chance to contribute to innovative research that could enhance heart attack diagnosis.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Studies have shown that the AliveCor 12-lead ECG System performs as effectively as standard 12-lead ECG machines. It safely and accurately records heart signals. Healthcare settings have used the device to detect various heart conditions, including heart attacks. Tests with earlier versions demonstrated that the device functioned well without causing patient issues. It quickly identifies serious heart problems, aiding in timely care. With FDA clearance for similar uses, the device is generally considered safe for use.¹²³⁴⁵

Most treatments for heart attacks involve medications like aspirin, beta-blockers, and nitrates, as well as procedures such as angioplasty. However, the AliveCor 12-lead ECG is unique because it offers a portable, smartphone-based method to quickly assess heart health. This innovation allows for real-time monitoring outside traditional medical settings, which could lead to faster diagnosis and treatment. Researchers are excited about this technology as it has the potential to improve accessibility and convenience, enabling earlier intervention and possibly better outcomes for patients experiencing heart attacks.

Research has shown that the AliveCor 12-lead ECG system, which participants in this trial will use, effectively diagnoses heart attacks, including STEMI and NSTEMI types. A previous study confirmed the device's accuracy by comparing it to standard 12-lead ECGs, finding similar results in most cases. The system quickly and accurately checks heart rhythms, making it a valuable tool in emergencies. Additionally, the device records an ECG faster than traditional methods. Overall, the AliveCor 12-lead ECG has proven its ability to effectively detect various heart problems.¹⁶⁷⁸⁹